Roche Says Xofluza Achieved Positive Results in Phase 3 Influenza Trial
Provided by
Dow Jones
By Ian Walker
Roche said its Xofluza treatment reduced the spread of influenza in a single dose during a Phase 3 trial, meeting its main goal.
The Swiss pharma giant said Thursday that a single oral dose of Xofluza significantly reduced the chance of other people in the same household catching the virus, and that no new safety signals were identified.
"We look forward to discussing these data with regulatory authorities and public health organizations for influenza pandemic preparedness to bring these benefits to patients," its chief medical officer and head of global product development, Levi Garraway, said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
September 19, 2024 01:31 ET (05:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States